Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Notice of FDA Advisory Committee Meeting on February 27, 2001

Valganciclovir Hydrochloride Tablets for Treatment of Cytomegalovirus (CMV) Retinitis

February 2, 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The FDA Antiviral Drugs Advisory Committee will meet on February 27, 2001, to discuss data related to the safety and effectiveness of valganciclovir hydrochloride 450 mg tablets, proposed for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. The drug sponsor is Syntex (USA).

This meeting is scheduled to take place from 9:00 a.m. to 5:30 p.m. at the Holiday Inn (the Ballrooms), 2 Montgomery Avenue, Gaithersburg, MD. You can contact the hotel directly at 301.948.8900 for directions or accommodation information.

The public is invited and encouraged to attend FDA advisory committee meetings. No registration is required.

Interested persons may present data, information, or views -- orally or in writing -- related to the consideration of valganciclovir for the treatment of CMV retinitis in patients with AIDS.

Advertisement
If you would like to make an oral presentation on February 27, please send the following information to Tara Turner, Pharm. D., Center for Drug Evaluation and Research (HFD-21), 5600 Fishers Lane, Rockville, MD 20857, 301.827.7001, e-mail TurnerT@cder.fda.gov, or by fax to 301.827.6776, by February 20, 2001.

  • Name of speaker (and organization/affiliation if appropriate)

  • Address, phone and fax numbers

  • A brief summary statement of your comments

  • Approximate amount of time you would like to speak

Oral presentations from the public are scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited, depending on the number of speakers.

Written information may be submitted to Dr. Turner at the same mailing or e-mail address, or by fax. Written information should also be received before February 20, 2001.

For up-to-date information about this meeting, please call the FDA Advisor Committee Information Line, 1.800.741.8138 (301.443.0572 in the Washington D.C. area) and press code 12531.

For general information, contact Richard Klein, Office of Special Health Issues, 301.827.4460, or e-mail Rklein@oc.fda.gov.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
 
See Also
More on the FDA Drug Approval Process and Other Regulatory Issues

Tools
 

Advertisement